Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497043 | 0.84 | MAPT (0.52) | HRH3APPTSHRMAPTKMT2A | |
| SCHEMBL992215 | 0.84 | PPARA (0.57) | PPARAPPARGHRH3APPTSHR | |
| SCHEMBL127737 | 0.83 | ALDH1A1 (0.52) | HRH3SLC22A12MAPTKMT2AKIF11 | |
| SCHEMBL28340064 | 0.82 | PPARA (0.56) | PPARAPPARGHRH3APPTSHR | |
| SCHEMBL479996 | 0.82 | CES2 (0.46) | PPARAPPARGHRH3APPTSHR | |
| SCHEMBL28806244 | 0.82 | ESR1 (0.52) | HRH3APPMAPTKMT2ASLC13A5 | |
| SCHEMBL127736 | 0.82 | HRH3 (0.43) | PPARAPPARGEPHX2HRH3APP | |
| SCHEMBL27511914 | 0.82 | KDM4E (0.46) | HRH3MAPTKMT2AKIF11BLM | |
| SCHEMBL10975329 | 0.82 | CA1 (0.44) | PPARAPPARGHRH3APPMAPT | |
| SCHEMBL7182175 | 0.82 | RXRA (0.54) | EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129408-B2 | Pharmaceutical composition for piperidinoalkanol compounds | AVENTISUB II INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7671071-B2 | Polymorphic Form XVI of fexofenadine hydrochloride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090149497-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICALS USA, INC. | 2009-06-11 | — | — | US | disclosed |
| CN-100475775-C | Highly pure bases of 3,3-diphenyl propylamine monoesters | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-04-08 | — | — | CN | disclosed |
| US-20090082398-A1 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-26 | — | — | US | disclosed |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICALS USA, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090012121-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-01-08 | — | — | US | disclosed |
| US-20090012301-A1 | FEXOFENADINE CRYSTAL FORM AND PROCESSES FOR ITS PREPARATION THEREOF | TEVA PHARMACEUTICALS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| CN-100441179-C | Transdermal administration of (r)-3,3-diphenylpropylamine monoesters. | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-12-10 | — | — | CN | disclosed |
| US-20070249671-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-25 | — | — | US | disclosed |
| CN-1802345-A | Highly pure bases of 3,3-diphenyl propylamine monoesters | SANOL ARZNEI SCHWARZ GMBH (DE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1767820-A | Transdermal administration of (r)-3,3-diphenylpropylamine monoesters. | SANOL ARZNEI SCHWARZ GMBH (DE) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012121-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | F5, CYP3A5, CYP4F8 | PPARA 3747/4885PPARG 4019/4885EPHX2 278/4885 |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | UBE2V1, XDH, F5 | PPARA 4399/4885PPARG 4347/4885EPHX2 3299/4885 |
| US-20070249671-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | PKD1, CFTR, PKD2 | PPARA 340/4885PPARG 449/4885EPHX2 3551/4885 |
| US-20090082398-A1 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | HRH2, CYP4F2, CYP4F3 | PPARA 4273/4885PPARG 4241/4885EPHX2 668/4885 |
| US-20090012301-A1 | FEXOFENADINE CRYSTAL FORM AND PROCESSES FOR ITS PREPARATION THEREOF | CYP4F3, CYP4F2, CYP2F1 | PPARA 4092/4885PPARG 4379/4885EPHX2 669/4885 |
| US-20090149497-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | F5, CYP3A5, CYP4F8 | PPARA 3803/4885PPARG 4105/4885EPHX2 277/4885 |
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | PKD1, CFTR, PKD2 | PPARA 340/4885PPARG 449/4885EPHX2 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.